NasdaqGS - Nasdaq Real Time Price • USD
Sarepta Therapeutics, Inc. (SRPT)
As of 12:37 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 13 | 13 | 14 | 15 |
| Avg. Estimate | -0.05 | 1.01 | 3.41 | 10.8 |
| Low Estimate | -0.43 | 0.04 | 0.89 | 0.52 |
| High Estimate | 0.54 | 2.59 | 6.3 | 25.35 |
| Year Ago EPS | -0.27 | -0.46 | -5.8 | 3.41 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 16 | 20 | 20 |
| Avg. Estimate | 383.76M | 495.89M | 1.88B | 2.82B |
| Low Estimate | 365.6M | 406.91M | 1.57B | 1.67B |
| High Estimate | 435M | 705.54M | 2.42B | 4.4B |
| Year Ago Sales | 261.24M | 331.82M | 1.24B | 1.88B |
| Sales Growth (year/est) | 46.90% | 49.40% | 51.60% | 49.80% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -1.78 | -1.23 | 0.01 | -0.07 |
| EPS Actual | -0.27 | -0.46 | 0.47 | 0.37 |
| Difference | 1.51 | 0.77 | 0.46 | 0.44 |
| Surprise % | 84.80% | 62.60% | 4,600.00% | 628.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.05 | 1.01 | 3.41 | 10.8 |
| 7 Days Ago | -0.13 | 0.6 | 2.29 | 10.55 |
| 30 Days Ago | -0.06 | 0.72 | 2.37 | 10.94 |
| 60 Days Ago | -0.06 | 0.72 | 2.13 | 10.16 |
| 90 Days Ago | 0.44 | 0.87 | 2.98 | 10.16 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 2 | 3 | 4 |
| Up Last 30 Days | 9 | 10 | 12 | 10 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | 1 | 1 | -- |
Growth Estimates
| CURRENCY IN USD | SRPT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 81.50% | -- | -- | 8.00% |
| Next Qtr. | 319.60% | -- | -- | 11.70% |
| Current Year | 158.80% | -- | -- | 5.40% |
| Next Year | 216.70% | -- | -- | 13.20% |
| Next 5 Years (per annum) | 96.00% | -- | -- | 11.06% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | JP Morgan: Overweight to Overweight | 5/3/2024 |
| Reiterates | Cantor Fitzgerald: Neutral to Neutral | 5/2/2024 |
| Reiterates | Needham: Buy to Buy | 5/2/2024 |
| Maintains | UBS: Buy to Buy | 3/1/2024 |
| Reiterates | Cantor Fitzgerald: Neutral to Neutral | 2/29/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 2/29/2024 |
Related Tickers
MDGL Madrigal Pharmaceuticals, Inc.
204.52
-6.17%
APLS Apellis Pharmaceuticals, Inc.
42.20
-3.87%
TGTX TG Therapeutics, Inc.
17.26
+0.46%
AXSM Axsome Therapeutics, Inc.
75.16
-2.32%
VKTX Viking Therapeutics, Inc.
77.40
-2.78%
BPMC Blueprint Medicines Corporation
108.16
-0.36%
VRTX Vertex Pharmaceuticals Incorporated
421.55
+2.76%
REGN Regeneron Pharmaceuticals, Inc.
960.11
-1.02%
ALNY Alnylam Pharmaceuticals, Inc.
154.72
+0.25%
ARDX Ardelyx, Inc.
8.84
-5.05%